Semaglutide

MASLD clinical update featured image: FIB-4 screening and two new MASH drug options

MASLD in Primary Care: The New AASLD and ADA Guidance for Screening and Treatment in 2026

By Dr. Anush S. Pillai, DO, FAAFP | Reviewed by CME Travel Academy Faculty 6 min read  ·  Reviewed September 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference In this article: Why MASLD Belongs on Your Cardiometabolic Radar The New Screening Pathway

MASLD in Primary Care: The New AASLD and ADA Guidance for Screening and Treatment in 2026 Read More »

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice

Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice Read More »